Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Fleury sur Orne, France Clinical Trials

A listing of Fleury sur Orne, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (58) clinical trials

Study to Evaluate the Effect of Lixisenatide in Patient With Parkinson's Disease

This study will be a French, multicenter parallel groups, 2-arm, randomized, placebo-controlled, double-blind, proof-of-concept (POC) phase II trial evaluating the effect of lixisenatide, in patients with early PD. The treatment period will be followed by a wash-out period of 2 months. JUSTIFICATION/CONTEXT Parkinson's disease (PD) is a common neurodegenerative disease. ...

Phase

2.36 miles

Learn More »

This Study Tests Whether BI 425809 Together With Brain Training Using a Computer Improves Mental Functioning in Patients With Schizophrenia

The primary objective of this Phase II exploratory trial is to provide Proof of Concept (PoC) data to assess the effect on cognition of oral once daily administration of BI 425809 given for 12 weeks in patients with schizophrenia on stable antipsychotic treatment and adjunctive Computerized Cognitive Training (CCT).

Phase

2.36 miles

Learn More »

A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)

The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment with angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs). These patients are ...

Phase

2.36 miles

Learn More »

A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer

The main purpose of this study is to evaluate the anti-tumor activity of bempegaldesleukin (NKTR-214) in combination with nivolumab by assessing the objective response rate (ORR) in cisplatin ineligible, locally advanced or metastatic urothelial cancer patients.

Phase

2.36 miles

Learn More »

Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare and highly aggressive subtype of locally advanced breast cancer representing approximately 5% of all breast cancers that requires immediate aggressive treatment. Significant progress has been made in recent years using a combination of treatments, including neoadjuvant chemotherapy, surgery and radiation therapy. Accumulating data ...

Phase

2.36 miles

Learn More »

Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)

Adult patients with a histologically or cytologically documented advanced NSCLC not amenable to curative surgery or radiation with tumors that lack activation EGFR mutations and ALK fusions are eligible for enrollment. During the initial therapy phase, patients will receive treatment with Durvalumab along with the Investigator's choice of platinum-based doublet ...

Phase

2.36 miles

Learn More »

Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer

Immune chekpoints (ICI) are evaluated in many digestive cancers. Certain types of cancer appear to be rather refractory to ICI such as colorectal cancers (CRC). However, the MSI CRC representing approximately 15% of the CRCs exhibits a high mutational load which generates many potentially immunogenic neoantigens. In addition, strong expression ...

Phase

2.36 miles

Learn More »

Phase II Study of Regorafenib as Maintenance Therapy

Patients will be randomized 1:1 using a centralized randomization software, assuring concealment, with a minimization program controlling for the following factors: Histological subgroups: leiomyosarcoma versus synovial sarcoma versus other histological subtype Response to doxorubicin-based chemotherapy: partial response versus stable disease Centers The treatment will be administrated as long as it ...

Phase

2.36 miles

Learn More »

Stereotactic Radiotherapy for Cerebral Metastases With Recent Hemorrhagic Signal

This prospective 2-stage, non-randomized Phase 2 trial evaluates the safety and efficacy of FSRT for the management of hemorrhagic brain metastases

Phase

2.36 miles

Learn More »

A Study to Assess the Ability of Eltrombopag to Induce Sustained Remission in Subjects With ITP

This study will assess the ability of eltrombopag to induce sustained treatment-free remission in ITP subjects who relapsed or failed to respond to an initial treatment with steroids. There is limited, mainly retrospective evidence that earlier use of eltrombopag after ITP diagnosis, will allow a larger proportion of subjects to ...

Phase

2.36 miles

Learn More »